Literature DB >> 30498414

Mortality, Morbidity and Related Outcomes Following Perioperative Blood Transfusion in Patients with Major Orthopaedic Surgery: A Systematic Review.

Susanne Müller1, Doris Oberle1, Ursula Drechsel-Bäuerle1, Jutta Pavel1, Brigitte Keller-Stanislawski1, Markus B Funk1.   

Abstract

BACKGROUND: Benefits and risks of liberal and restrictive transfusion regimens are under on-going controversial discussion. This systematic review aimed at assessing both regimens in terms of pre-defined outcomes with special focus on patients undergoing major orthopaedic surgery.
METHODS: We performed a literature search for mortality, morbidity and related outcomes following peri-operative blood transfusion in patients with major orthopaedic surgery in electronic databases. Combined outcome measure estimates were calculated within the scope of meta-analyses including randomised clinical trials comparing restrictive versus liberal blood transfusion regimens (e.g. MH risk ratio, Peto odds ratio).
RESULTS: A total of 880 publications were identified 15 of which were finally included (8 randomised clinical trials (RCTs) with 3,693 patients and 6 observational studies with 4,244,112 patients). Regarding RCTs, no significant differences were detected between the transfusion regimes for all primary outcomes (30-day mortality, thromboembolic events, stroke/transitory ischaemic attack, myocardial infarction, wound infection and pneumonia) and a secondary outcome (length of hospital stay), whereas there was a significantly reduced risk of receiving at least one red blood concentrate under a restrictive regimen.
CONCLUSION: The results of this systematic review do not suggest an increased risk associated with either a restrictive or a liberal transfusion regimen in patients undergoing major orthopaedic surgery.

Entities:  

Keywords:  Erythrocyte transfusion; Haemovigilance; Immunomodulation; Meta-analyses; Non-haemolytic transfusion reactions; Peri-operative period; Restrictive and liberal transfusion regimes; Systematic review

Year:  2018        PMID: 30498414      PMCID: PMC6257151          DOI: 10.1159/000481994

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  31 in total

1.  Liberal or restrictive transfusion in high-risk patients after hip surgery.

Authors:  Jeffrey L Carson; Michael L Terrin; Helaine Noveck; David W Sanders; Bernard R Chaitman; George G Rhoads; George Nemo; Karen Dragert; Lauren Beaupre; Kevin Hildebrand; William Macaulay; Courtland Lewis; Donald Richard Cook; Gwendolyn Dobbin; Khwaja J Zakriya; Fred S Apple; Rebecca A Horney; Jay Magaziner
Journal:  N Engl J Med       Date:  2011-12-14       Impact factor: 91.245

2.  Patient Blood Management is Associated With a Substantial Reduction of Red Blood Cell Utilization and Safe for Patient's Outcome: A Prospective, Multicenter Cohort Study With a Noninferiority Design.

Authors:  Patrick Meybohm; Eva Herrmann; Andrea U Steinbicker; Maria Wittmann; Matthias Gruenewald; Dania Fischer; Georg Baumgarten; Jochen Renner; Hugo K Van Aken; Christian F Weber; Markus M Mueller; Christof Geisen; Julia Rey; Dimitra Bon; Gudrun Hintereder; Suma Choorapoikayil; Johannes Oldenburg; Christian Brockmann; Raoul G Geissler; Erhard Seifried; Kai Zacharowski
Journal:  Ann Surg       Date:  2016-08       Impact factor: 12.969

Review 3.  Red blood cell transfusion for people undergoing hip fracture surgery.

Authors:  Susan J Brunskill; Sarah L Millette; Ali Shokoohi; E C Pulford; Carolyn Doree; Michael F Murphy; Simon Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2015-04-21

4.  Incidence and risk factors for allogenic blood transfusion during major joint replacement using an integrated autotransfusion regimen. The Rizzoli Study Group on Orthopaedic Anaesthesia.

Authors:  B Borghi; A Casati
Journal:  Eur J Anaesthesiol       Date:  2000-07       Impact factor: 4.330

Review 5.  Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion.

Authors:  Jeffrey L Carson; Paul A Carless; Paul C Hebert
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

6.  Risk factors for postoperative infections in patients with hip fracture treated by means of Thompson arthroplasty.

Authors:  F García-Alvarez; R Al-Ghanem; I García-Alvarez; A López-Baisson; M Bernal
Journal:  Arch Gerontol Geriatr       Date:  2009-02-23       Impact factor: 3.250

7.  The effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery.

Authors:  Nicolai B Foss; Morten Tange Kristensen; Pia Søe Jensen; Henrik Palm; Michael Krasheninnikoff; Henrik Kehlet
Journal:  Transfusion       Date:  2009-02       Impact factor: 3.157

8.  A randomized comparison of transfusion triggers in elective orthopaedic surgery using leucocyte-depleted red blood cells.

Authors:  C So-Osman; R Nelissen; R Te Slaa; L Coene; R Brand; A Brand
Journal:  Vox Sang       Date:  2009-07-23       Impact factor: 2.144

9.  Primary total knee arthroplasty allogenic transfusion trends, length of stay, and complications: nationwide inpatient sample 2000-2009.

Authors:  Alison K Klika; Travis J Small; Anas Saleh; Caleb R Szubski; Aiswarya Lekshmi Pillai Chandran Pillai; Wael K Barsoum
Journal:  J Arthroplasty       Date:  2014-06-28       Impact factor: 4.757

10.  Perioperative transfusion threshold and ambulation after hip revision surgery--a randomized trial.

Authors:  Kamilla Nielsen; Pär I Johansson; Benny Dahl; Michael Wagner; Britt Frausing; Jens Børglum; Kenneth Jensen; Jens Stürup; Jesper Hvolris; Lars S Rasmussen
Journal:  BMC Anesthesiol       Date:  2014-10-10       Impact factor: 2.217

View more
  1 in total

1.  Systematic reviews and meta-analyses comparing mortality in restrictive and liberal haemoglobin thresholds for red cell transfusion: an overview of systematic reviews.

Authors:  Kevin M Trentino; Shannon L Farmer; Michael F Leahy; Frank M Sanfilippo; James P Isbister; Rhonda Mayberry; Axel Hofmann; Aryeh Shander; Craig French; Kevin Murray
Journal:  BMC Med       Date:  2020-06-24       Impact factor: 8.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.